Physician profile
Mark Gesell
NPI 1083654990
$5,446.88
in general payments reported to CMS, 2019-2025
8 companies · $601 in 2025
The $601 reported for 2025 was more than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,044 · 2020: $13.77 · 2021: $259 · 2022: $970 · 2023: $73.54 · 2024: $1,486 · 2025: $601.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,543 · Travel and Lodging: $618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,542.70 |
| Travel and Lodging | $617.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $3,452.96 | 2019-2025 | Mako, Triathlon, Accolade |
| Smith+Nephew, INC. | $1,607.49 | 2019-2025 | Real Intelligence, Journey II, Redapt |
| Heron Therapeutics, INC. | $151.75 | 2021-2023 | Zynrelef |
| Depuy Synthes Sales INC. | $127.13 | 2022 | |
| Endo Pharmaceuticals INC. | $57.68 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $22.39 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $16.93 | 2023 | Iovera, Exparel, Zilretta |
| Biocomposites INC | $10.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Gesell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.